JDD Podcast
Perspectives on Managing Moderate-to-Severe Atopic Dermatitis
Drs. April Armstrong, Lawrence Eichenfield & Adam Friedman
- Discuss management strategies for patients with moderate-to-severe atopic dermatitis
- Identify common co-morbidities of atopic dermatitis and strategies for optimal patient care
April W. Armstrong, MD, MPH – No disclosures.
Lawrence F. Eichenfield, MD – Grant/Research Support: Abbvie, Pfizer, Regeneron, Sanofi-Genzyme, Ortho Derm, Verrica. Consultant: Almirall, Arcutis, Asana, Dermavant, Dermira, Forte, Galderma, Incyte, Leo Pharma, Lilly, Novartis, OrthoDerm. Speakers’ Bureau: Pfizer, Regeneron, Sanofi-Genzyme.
Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
You May Also Like
Get More from the JDD Podcast
Get the latest dermatology news delivered straight to your Inbox – sign up for the JDD Newsletter.
Discover the latest research, exclusive articles from leading dermatology experts,popular Podcast episodes, free CME activities, and more!
Error: No feed found.
Please go to the Instagram Feed settings page to create a feed.
